in , , , ,

NIAID Awards 5M for Non-Traditional Bacterial Infection Treatments

Immune Response Decoy Target
Credit: Shutterstock

The National Institute of Allergy and Infectious Diseases (NIAID) has awarded approximately $5 million in funding for 24 research projects seeking to develop non-traditional therapeutics for bacterial infections to help address the growing health threat of antibiotic resistance.

Increasing resistance to antibiotics coupled with the slow pace of new antibiotic development threatens to erode the past 70 years of progress in fighting life-threatening bacterial infections. The overuse and abuse of antibiotics drives this issue and, as a consequence, bacteria adapt to antibiotics designed to destroy them, making the drugs less effective and allowing antibiotic-resistant strains to survive and multiply.

Non-traditional therapeutics are antibacterial treatment that works differently than traditional antibiotics, such as use of therapeutic bacteria, phage therapy, or decoy targets. The effort supports the goals outlined in the President’s National Action Plan for Combating Antibiotic-Resistant Bacteria.

The 24 phased innovation awards were made to 18 academic institutions and three industrial organizations. The awards provide support for two years with the possibility of three additional years of funding for the most accomplished projects. The recipients are as follows:

“New strategies are desperately needed to treat patients with antibiotic-resistant infections that often are deadly,” said NIAID Director Anthony S. Fauci, M.D. “These new NIAID grants will provide funding to researchers developing unique, non-traditional therapies that could complement or even replace currently available antibiotics that are losing effectiveness.”

Quantitative Viral Outgrowth Assay

Rapid Screening Method to Identify Ebola Drugs

NBAF National Bio and Agro-Defense Facility

OPTIC Contract for National Bio and Agro-Defense Facility